Inflammatory molecule reduction with hydroxyurea therapy in children with sickle cell anemia

Rhiannon R. Penkert, Julia L. Hurwitz, Paul Thomas, Jason Rosch, Jola Dowdy, Yilun Sun, Li Tang, and Jane S. Hankins

Disclosures: Jason Rosch receives consulting fees from SeLux diagnostics, Jola Dowdy receives research support from Alexion, Jane Hankins receives research support from Novartis and Global Blood Therapeutics and consulting fees from Bluebird Bio, Paul Thomas receives research support from Genetech and consulting fees from Flagship Ventures and GSK, and Julia Hurwitz received consulting fees from Merck in 2015.

Contributions: Rhiannon R. Penkert: conducted inflammatory molecules analysis, statistical analysis, data interpretation, and wrote manuscript Julia L. Hurwitz: conducted inflammatory molecules analysis, data interpretation, and wrote manuscript Paul Thomas: conducted inflammatory molecules analysis, data interpretation, and edited manuscript Jason Rosch: conducted inflammatory molecules analysis, data interpretation, and edited manuscript Jola Dowdy: data collection, regulatory issues, and edited the manuscript Yilun Sun: statistical analysis, and edited the manuscript Li Tang: statistical analysis, and edited the manuscript Jane S. Hankins: study concept, data collection, data interpretation, and wrote manuscript.